New combo therapy gives hope to melanoma patients who failed standard treatment

NCT ID NCT02965716

First seen Nov 18, 2025 · Last updated May 14, 2026 · Updated 24 times

Summary

This study tests whether combining two immunotherapy drugs—T-VEC (a virus-based therapy injected into tumors) and pembrolizumab (an antibody given by IV)—can shrink tumors in people with advanced melanoma that no longer responds to standard immunotherapy. About 43 adults with stage III or IV melanoma that cannot be surgically removed are participating. The goal is to see if this combination can control the disease and provide lasting responses.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for STAGE III CUTANEOUS MELANOMA AJCC V7 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Allegiance Health

    Jackson, Michigan, 49201, United States

  • CTCA at Western Regional Medical Center

    Goodyear, Arizona, 85338, United States

  • Henry Ford Cancer Institute-Downriver

    Brownstown, Michigan, 48183, United States

  • Henry Ford Hospital

    Detroit, Michigan, 48202, United States

  • Henry Ford Macomb Hospital-Clinton Township

    Clinton Township, Michigan, 48038, United States

  • Henry Ford West Bloomfield Hospital

    West Bloomfield, Michigan, 48322, United States

  • Huntsman Cancer Institute/University of Utah

    Salt Lake City, Utah, 84112, United States

  • Indiana University/Melvin and Bren Simon Cancer Center

    Indianapolis, Indiana, 46202, United States

  • Kansas City Veterans Affairs Medical Center

    Kansas City, Missouri, 64128, United States

  • Keck Medical Center of USC Pasadena

    Pasadena, California, 91105, United States

  • Los Angeles General Medical Center

    Los Angeles, California, 90033, United States

  • Loyola University Medical Center

    Maywood, Illinois, 60153, United States

  • Ohio State University Comprehensive Cancer Center

    Columbus, Ohio, 43210, United States

  • UCLA / Jonsson Comprehensive Cancer Center

    Los Angeles, California, 90095, United States

  • USC / Norris Comprehensive Cancer Center

    Los Angeles, California, 90033, United States

  • University of Cincinnati Cancer Center-UC Medical Center

    Cincinnati, Ohio, 45219, United States

  • University of Cincinnati Cancer Center-West Chester

    West Chester, Ohio, 45069, United States

  • University of Kansas Hospital-Westwood Cancer Center

    Westwood, Kansas, 66205, United States

  • University of South Alabama Mitchell Cancer Institute

    Mobile, Alabama, 36688, United States

  • Vanderbilt University/Ingram Cancer Center

    Nashville, Tennessee, 37232, United States

Conditions

Explore the condition pages connected to this study.